Adial Pharmaceuticals, Inc

Adial Pharmaceuticals acquired Azora Therapeutics and secured up to $64 million in financing to advance AT177, a colon-targeted AhR agonist for ulcerative colitis treatment. The deal includes $32 million upfront and potential $32 million in milestone-based funding, with Phase 1 clinical trials planned for mid-2027. The company also appointed Wend...

The alcohol use disorder (AUD) market is projected to grow at a 12.1% CAGR from 2026-2036, driven by novel therapeutic mechanisms and new drug approvals. The market was valued at USD 1.1 billion in 2025 across seven major markets. Key emerging therapies from companies like Adial Pharmaceuticals, Eli Lilly, MediciNova, and Altimmune are expected t...

The peripheral T-cell lymphoma (PTCL) treatment market is projected to grow at a 7% CAGR through 2036, driven by increasing disease incidence and expanding patient populations. The market was valued at USD 800 million in 2025, with the US accounting for 68% of the market. Multiple emerging therapies from major pharmaceutical companies are expecte...

Adial Pharmaceuticals announced the publication of an international patent application for AD04, its lead investigational drug for treating Alcohol Use Disorder in heavy drinking patients. The patent, once granted, is expected to protect the company's core assets through at least 2045. The patent application is based on treatment of populations i...

Adial Pharmaceuticals' CEO Cary Claiborne was featured on the Big Biz Show, discussing the company's clinical-stage biopharmaceutical work in addiction treatment, specifically highlighting their investigational drug AD04 for Alcohol Use Disorder.